EUVIMEDEUVIMED entdecken
Editorial

Why Was the Azithromycin “for Life” Trial Necessary?

Kathryn Maitland iD, A Sarah Walker iD

New England Journal of Medicine · 2024

DOI: 10.1056/nejme2407000 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Kathryn Maitland und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College (K.M.), and the Medic…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Mass Drug Administration, Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzithromycinMass Drug AdministrationBacterial InfectionsHumansRandomized Controlled Trials as TopicInfantChild, PreschoolNigerInfant MortalityChild MortalityChemopreventionDrug Resistance, Bacterial

Substanzen

Anti-Bacterial AgentsAzithromycin

Autor:innen und Institutionen

  • From the Department of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College (K.M.), and the Medical Research Council Clinical Trials Unit, University College London (A…

ORCID-Profile: Kathryn Maitland, A Sarah Walker

Zitieren

APA

Maitland, K., & Walker, A. S. (2024). Why Was the Azithromycin “for Life” Trial Necessary?. New England Journal of Medicine. https://doi.org/10.1056/nejme2407000

Vancouver

Maitland K, Walker AS. Why Was the Azithromycin “for Life” Trial Necessary?. New England Journal of Medicine. 2024. doi:10.1056/nejme2407000

BibTeX
@article{Maitland2024,
  author = {Maitland, Kathryn and Walker, A Sarah},
  title = {Why Was the Azithromycin “for Life” Trial Necessary?},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejme2407000}
}
Kostenlos starten →